Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Abterra Biosciences
AddedFeb 16, 2024
UpdatedJun 18, 2026
Abterra Biosciences

Abterra Biosciences

Seed

Abterra Bio: Pioneering next-gen antibody therapeutics with advanced technology and machine learning.

HQ
San Diego, CA, US
Founded
2009
Overview
Compare
Fundraising
Employees
Website

Abterra Biosciences is dedicated to advancing the field of antibody therapeutics through cutting-edge technology. The company employs next-generation sequencing, mass spectrometry, and machine learning to map antibody responses comprehensively. This approach enables the rapid identification of superior therapeutic antibodies for infectious diseases and cancer. With a focus on truly human antibody therapeutics, Abterra Bio aims to revolutionize how these treatments are developed.

Abterra Biosciences has assembled an interdisciplinary team of data scientists and biologists to drive innovation in antibody therapeutics. Their technology is built on decades of experience, positioning them as a leader in the industry. By leveraging advanced methodologies, Abterra Bio has made significant strides in identifying effective therapeutic antibodies, contributing to improved healthcare outcomes.

Abterra Biosciences - Similar Companies

Abpro logo

Abpro

BigHat Biosciences logo

BigHat Biosciences

bighatbio.com

OmniAb logo

OmniAb

omniab.com

Nabla Bio logo

Nabla Bio

nabla.bio

AbCellera Biologics logo

AbCellera Biologics

abcellera.com

Abreos Biosciences logo

Abreos Biosciences

abreos.com

Global Bio logo

Global Bio

Zebra Biologics logo

Zebra Biologics

Amberstone Biosciences logo

Amberstone Biosciences

amberstonebio.com

AltruBio logo

AltruBio

BioLoomics logo

BioLoomics

bioloomics.com

Amagma logo

Amagma

Abalone Bio logo

Abalone Bio

abalonebio.com

Dren Bio logo

Dren Bio

drenbio.com

TenSixty Biosciences logo

TenSixty Biosciences

tensixty.bio

Abterra Biosciences - Quick Facts

Who are Abterra Biosciences' competitors?

Companies similar to Abterra Biosciences include Abpro, BigHat Biosciences, OmniAb and Nabla Bio.

When was Abterra Biosciences founded?

Abterra Biosciences was founded in 2009.

Where is Abterra Biosciences' headquarters located?

Abterra Biosciences' headquarters is located in San Diego, CA, US.

When was Abterra Biosciences' last funding round?

Abterra Biosciences' most recent funding round was for $1.6M (USD) in February 2021.

How much has Abterra Biosciences raised to-date?

As of Feb 15, 2021, Abterra Biosciences has raised a total of $4.4M (USD).

How many employees does Abterra Biosciences have?

Abterra Biosciences has 9 employees as of Feb 4, 2024.

Abterra Biosciences - Classification

Industry
  • Professional Service Companies
Ownership
  • Private
  • Venture Capital
Technology
  • AI
  • Machine Learning
Geographic Exposure
  • Global
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Antibody Therapeutics
Tags
  • Biotech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 5 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 7372Prepackaged Software